To The Moon

$Rocket Lab USA, Inc.(RKLB)$ 

🚀!

🐶 My take: Rocket Lab delivered a mixed set of Q3 2026 results. Revenue and gross profit margins came in better than expected, and Q4 guidance also looks encouraging. However, investors are disappointed because the highly anticipated Neutron rocket maiden flight has been delayed to 2027.

For me, this is a reminder that in the stock market, good earnings do not always mean a higher share price. Investors are not just buying today’s revenue. They are buying expectations of tomorrow’s growth.

📊 1. Revenue is growing, but Launch needs to catch up

Rocket Lab reported revenue of US$268 million, approximately 4% above market expectations.

The main growth driver was Space Systems, while Launch revenue disappointed.

However, I don’t think this automatically means demand is weakening.

* 54 launches were booked during the quarter.

* 8 of those bookings were for Neutron.

* Electron launch base pricing increased from US$55 million to US$70 million.

🐶 To me, the interesting point is pricing power. Customers are still booking launches, and Rocket Lab is increasing prices. Demand appears healthy, but the company needs to convert those orders into actual revenue.

💰 2. Gross profit margin surprised investors

Rocket Lab achieved a GAAP gross profit margin of 33.6%, beating even the upper end of management’s previous guidance.

This is encouraging because:

* Higher-margin Space Systems components contributed to profitability.

* More frequent Electron launches helped improve economies of scale.

* The Mynaric acquisition created some additional pressure.

Management expects Q4 gross margins to improve further to 34%–36%.

🐶 I like seeing improving margins because revenue growth alone is not enough. Eventually, a company must demonstrate that it can turn sales into profits.

⚠️ 3. The problem: Operating expenses are rising

Here is where investors became less excited.

Operating expenses were approximately US$20 million above the high end of guidance.

Two important contributors were:

* Iridium transaction costs of approximately US$21 million.

* Higher Neutron research and development spending.

Operating loss widened to US$79 million.

Q4 EBITDA loss guidance was also weaker than expected, with a midpoint of US$17 million.

🐶 My concern is that Rocket Lab is spending heavily today for a product that has yet to fly commercially. If Neutron keeps getting delayed, investors will become less patient.

🚀 4. Neutron is the real story

Neutron is Rocket Lab’s biggest long-term opportunity.

The company wants to move beyond smaller Electron rockets and compete in the larger launch market.

But the maiden flight has now slipped to 2027, without a specific launch date.

Management wants to complete first-stage tank testing before providing a firmer schedule.

The company still maintains its ambition of generating US$1 billion in Neutron revenue within 3–5 years.

However, I must remember that projections are not guaranteed revenue.

The next important milestones are the hydrostatic and cryogenic tank tests expected in Q1 2027.

If these tests are successful, investor confidence could improve.

🐶 5. What Options Puppy thinks

I see two sides to Rocket Lab.

The bullish side:

* Strong launch bookings.

* Higher launch pricing.

* Growing Space Systems business.

* Improving gross margins.

* Neutron could open a much larger commercial opportunity.

The bearish side:

* Neutron has been delayed again.

* Operating expenses are rising.

* EBITDA losses remain.

* Positive free cash flow is pushed further out.

* Investors may demand a bigger discount because of execution risks.

For me, Rocket Lab is a company with an interesting long-term opportunity, but I don’t want to confuse an exciting business story with an attractive entry price.

1️⃣ Why am I making this trade now?

My interest in Rocket Lab comes from the growing space economy.

Satellite communications, defence contracts, launch services and space infrastructure could become important growth industries over the coming years.

However, after this earnings report, I would be more cautious about chasing the stock.

I want to see whether the market has already priced in the Neutron delay and whether buyers return after the initial disappointment.

2️⃣ What’s my plan from here?

My plan is to watch three things:

* Neutron testing: Successful tank tests could restore confidence.

* Space Systems growth: I want to see whether this business continues supporting revenue and margins.

* Cash flow: I want evidence that Rocket Lab can gradually reduce its operating losses.

I would rather wait for better confirmation than rush into buying simply because the company operates in an exciting industry.

🐶 Final thoughts from Options Puppy

Rocket Lab has not suddenly become a bad company because Neutron was delayed.

Its Space Systems business is growing, launch bookings remain strong, and pricing power is encouraging.

But the market wants execution, not just promises.

My takeaway: Good revenue, improving margins, but Neutron remains the make-or-break catalyst.

Sometimes the best trade is not buying immediately. Sometimes it is keeping my cash ready and waiting for the next opportunity. 🐶🚀

This is my earnings interpretation, not a recommendation to buy or sell RKLB. Options premiums, volatility and assignment risk should also be considered before selling puts.

$iShares Russell 2000 ETF(IWM)$  

$Rocket Companies(RKT)$  

@Shernice軒嬣 2000 @AI_FocusedTrader @WallStreet_Tiger @Tiger_Futures Captain 

Find out more here: Join me on Tiger Trade!

Sign up with my invite and we both get USD 220*! You’ll also unlock up to SGD 1,000 in welcome perks.